GSK plc GLAXF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.78% | 9.20% | 7.52% | 5.90% | 3.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.78% | 9.20% | 7.52% | 5.90% | 3.42% |
| Cost of Revenue | 1.80% | 5.39% | 4.47% | 5.66% | 7.61% |
| Gross Profit | 11.55% | 10.68% | 8.72% | 6.00% | 1.86% |
| SG&A Expenses | -10.81% | -12.57% | -14.41% | -14.96% | 17.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -270.77% | -392.67% | -173.97% | 17.69% | 62.91% |
| Total Operating Expenses | -5.18% | -5.47% | -5.03% | -1.81% | 15.43% |
| Operating Income | 64.07% | 70.46% | 59.64% | 33.63% | -26.75% |
| Income Before Tax | 32.76% | 86.79% | 121.19% | 121.45% | -5.72% |
| Income Tax Expenses | 4.60% | 95.38% | 119.42% | 120.98% | -7.52% |
| Earnings from Continuing Operations | 37.25% | 85.41% | 121.50% | 121.52% | -5.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 18.59% | -13.34% | -56.98% | -73.68% | -103.71% |
| Net Income | 46.45% | 96.69% | 131.02% | 128.01% | -13.09% |
| EBIT | 64.07% | 70.46% | 59.64% | 33.63% | -26.75% |
| EBITDA | 35.61% | 43.28% | 43.81% | 32.76% | -9.80% |
| EPS Basic | 48.29% | 99.03% | 132.20% | 128.62% | -13.33% |
| Normalized Basic EPS | 86.50% | 88.01% | 67.53% | 34.97% | -35.16% |
| EPS Diluted | 47.69% | 98.16% | 131.46% | 128.01% | -13.29% |
| Normalized Diluted EPS | 86.15% | 87.62% | 67.11% | 34.70% | -35.16% |
| Average Basic Shares Outstanding | -1.36% | -1.16% | -0.64% | -0.11% | 0.33% |
| Average Diluted Shares Outstanding | -1.26% | -1.05% | -0.52% | 0.01% | 0.43% |
| Dividend Per Share | 11.90% | 13.53% | 11.65% | 8.08% | 7.93% |
| Payout Ratio | -0.24% | -0.44% | -0.53% | -0.52% | 0.25% |